Trials / Unknown
UnknownNCT02972528
The Use of Allogenic Platelet Rich Plasma for the Treatment of Diabetic Foot Ulcer
Allogeneic Defibrinated Platelet Rich Plasma Lysate for the Healing of Chronic Diabetic Foot Ulcer
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hanan Jafar · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Allogenic defibrinated platelet rich plasma lysate will be injected in patients diagnosed with Diabetic Foot Ulcer (DFU).
Detailed description
In this study, allogenic, defibrinated platelet rich plasma lysate will be used as a direct injection into the periphery of diabetic chronic foot ulcers which have not healed using standard of care. Investigators anticipate a significant response in treated individuals measured by the percentage of skin restoration achieved.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Platelet Lysate | Direct injection of allogenic Platelet Lysate |
| BIOLOGICAL | Platelet Poor Plasma | Direct injection of allogenic Platelet Poor Plasma |
Timeline
- Start date
- 2018-02-03
- Primary completion
- 2020-02-01
- Completion
- 2020-09-01
- First posted
- 2016-11-23
- Last updated
- 2019-08-28
Locations
1 site across 1 country: Jordan
Source: ClinicalTrials.gov record NCT02972528. Inclusion in this directory is not an endorsement.